Executive Committee Responsibilities. The Executive Committee shall have the following responsibilities:
(a) to periodically review the Collaborative Research Plan from a strategic perspective, including consideration of expanding or contracting the Collaboration Therapeutic Areas;
(b) to review changes to the Collaborative Research Plan made by the Joint Research Committee or an Operating Committee as permitted by Sections 2.6.2 and 2.7.2, respectively, and to resolve any matters related thereto that are appealed to the Executive Committee by the Joint Research Committee or an Operating Committee;
(c) to periodically review the progress and results of the Collaboration to ensure that the Parties are meeting their commitments for both human and financial support and are each fulfilling all of their respective contractual obligations;
(d) to attempt to resolve any disagreements between the Parties with respect to the research conducted under the Collaboration, including those disagreements referred to it by the Joint Research Committee, the IP Committee or any Operating Committee;
(e) to approve changes to the allocation of Collaboration Funds set forth in the Collaborative Research Plan between the Target Validation Program and Antisense Drug Discovery Program, on the one hand, and the Reagent Provision Program, on the other hand;
(f) to approve changes to the assignment of Collaboration Funds and Collaboration FTEs between the Collaboration Therapeutic Areas as set forth in the Collaborative Research Plan;
(g) to propose to Lilly changes in the amount and/or timing of funding under the Loan Agreement as provided for in Sections 9.1.5 and 9.1.6, in the unexpected event that such is necessary;
(h) to provide guidance to the Joint Research Committee as to the data package required by Lilly in considering a Development Candidate for further development and commercialization efforts; and
(i) to establish and oversee an intellectual property committee that will operate in accordance with Section 2.7.2.
Executive Committee Responsibilities. The executive committee shall provide strategic direction to Mycosol and shall review and approve all budgets of Mycosol and any amendments thereto. The executive committee will approve the strategic direction of Mycosol, including the review and approval of all research and development plans and Mycosol business plans and any amendments thereto. Mycosol shall submit a research and development plan and a business plan to the executive committee for review and approval in respect of each fiscal year of Mycosol. A copy of the current Mycosol business plan is attached to this Agreement as Schedule 11.3. The executive committee will oversee the operations of Mycosol, including review and approval of any licensing opportunities or disposal of assets out of the ordinary course of business.
Executive Committee Responsibilities. The Executive Committee shall have the following responsibilities:
(a) to review the Collaborative Research Plan from a strategic perspective;
(b) to review the progress and results of the Collaboration to ensure that the Parties are meeting their commitments for both human and financial support and are each fulfilling all of their respective contractual obligations;
(c) to attempt to resolve any disagreements between the Parties with respect to the research conducted under the Collaboration;
(d) to optimize the value of the intellectual property arising from the Collaboration.
(e) to review the Collaborative Research Plan from a scientific and operational perspective;
(f) to make changes to the portions of the Collaborative Research Plan relating to the Target Validation Program and the Antisense Drug Discovery Program as it deems necessary to accomplish the purpose of the Collaboration;
(g) to prioritize and monitor progress of antisense lead identification for the Target Validation Program and Drug Discovery Program; provided, however, that if there is a disagreement concerning the prioritization of a Validation Target, such disagreement shall be decided by Lilly;
(h) to review the qualifications of the Collaboration FTEs to ensure that the Parties are meeting the intent of the Collaborative Research Plan;
(i) to approve changes to the allocation of Collaboration Funds set forth in the Collaborative Research Plan between the Target Validation Program and the Antisense Drug Discovery Program;
(j) to review and approve the use of any Third Party in the Collaboration and expenses related thereto, including review and approval of any related Third Party contract;
(k) to review and monitor all results of the work performed under Collaboration, including scientific efforts of both Parties, and providing prioritization, oversight and direction regarding such work in accordance with the Collaborative Research Plan;
(l) to adopt and modify the Critical Success Factors related to a Collaboration Therapeutic Area either generally or specifically with respect to a Validation Target or a Drug Discovery Target as documented by approved Executive Committee minutes;
(m) to determine whether a Validation Target is an Accepted Validation Target or Rejected Validation Target or Abandoned Validation Target;
(n) to designate Drug Discovery Targets and Validation Targets; and
(o) to make a determination of whether a Drug Discovery ASO Compound meets the criteria for designat...
